-
Apr 22, 2024 | 02264-4/fulltext?rss=yes&sz=64)
europeanurology.com | Fred Saad |E. David Crawford |Luke T Nordquist |Maha Hussain |Bertrand Tombal |Karim Fizazi | +10 more
AbstractAddition of darolutamide to androgen deprivation therapy (ADT) and docetaxel significantly improved overall survival (OS) in ARASENS (NCT02799602). Here we report on prostate-specific antigen (PSA) responses and their association with outcomes. ARASENS is an international, double-blind, phase 3 study in patients with metastatic hormone-sensitive prostate cancer (mHSPC) randomized to darolutamide 600 mg orally twice daily (n = 651) or placebo (n = 654), both with ADT + docetaxel.
-
Apr 12, 2024 | 
urotoday.com | Karim Fizazi
Read the Full Video TranscriptAlicia Morgans: Hi, I am so excited to be here today with Professor Karim Fizazi, who is joining me from Gustave Roussy in France after a wonderful presentation at EAU 2024, also in France, in Paris this year, where we heard him talk about treating metastatic hormone-sensitive prostate cancer and the idea that it is beyond just counting metastases. So, Karim, thank you so much for being here today. And please let me know, where did this come from?
-
Feb 1, 2024 | 
jnm.snmjournals.org | Oliver Sartor |Karim Fizazi |Ken Herrmann |Michael Morris
Thank you for your interest in spreading the word on Journal of Nuclear Medicine. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas.
-
Nov 14, 2023 | 
ascopubs.org | Joaquin Mateo |Karim Fizazi |Fred Saad |Neal Shore
In all subgroups assessed, olaparib improved outcomes versus abiraterone or enzalutamide for patients with mCRPC with BRCA alterations whose disease had progressed on previous NHA. Olaparib was associated with longer rPFS (hazard ratio [HR], 0.22 [95% CI, 0.15 to 0.32]) and OS (HR, 0.63 [95% CI, 0.42 to 0.95]) than control.
-
Nov 14, 2023 | 
brnw.ch | Joaquin Mateo |Karim Fizazi |Fred Saad |Neal Shore
Although multiple treatment options exist for patients with metastatic castration-resistant prostate cancer (mCRPC), outcomes remain poor, with clinical trials reporting median overall survival (OS) of approximately 3 years after diagnosis and life expectancy in real-world practice of closer to 2 years.1-4 Therefore, developing new strategies, including precision medicine approaches, to treat these patients is important.
-
Aug 10, 2023 | 
futuremedicine.com | Maha Hussain |Cora Sternberg |Eleni Efstathiou |Karim Fizazi
Future OncologyAhead of PrintPlain Language Summary of PublicationOpen Access, , , , , , , , , , & AbstractWhat is this summary about? This is a summary of a research article originally published in the Journal of Urology. The PROSPER study involved men who had a type of advanced prostate cancer called non-metastatic castration-resistant prostate cancer (nmCRPC). In patients with nmCRPC, their prostate cancer keeps growing even after traditional hormone treatments.
-
Jun 23, 2023 | 
targetedonc.com | Karim Fizazi
Karim Fizazi, MD, a medical oncologist at Gustave Roussy and professor of oncology at the University of Paris-Saclay, discusses the toxicities seen with the combination of talazoparib (Talzenna) plus enzalutamide (Xtandi). Recently, the FDA approved talazoparib in combination with enzalutamide for the treatment of patients with homologous recombination repair (HRR) gene-mutated metastatic castration resistant prostate cancer based on findings from the phase 3 TALAPRO-2 trial (NCT03395197).
-
Jun 21, 2023 | 
targetedonc.com | Karim Fizazi
Karim Fizazi, MD, a medical oncologist at Gustave Roussy and professor of oncology at the University of Paris-Saclay, discusses findings from the phase 3 TALAPRO-2 trial (NCT03395197) which support the recent FDA approval of talazoparib (Talzenna) plus enzalutamide (Xtandi) for the treatment of patients with homologous recombination repair (HRR) gene-mutated metastatic castration resistant prostate cancer.
-
Jun 16, 2023 | 
urotoday.com | Karim Fizazi
Read the Full Video TranscriptAlicia Morgans: Hi, I'm so thrilled to be here with Professor Karim Fizazi who is a GU medical oncologist and professor of oncology at Gustave Roussy in Paris. Thank you so much for being here with me. Karim Fizazi: Thank you, Alicia. Alicia Morgans: Wonderful. Karim, you, again, bring some wonderful and highly anticipated work to ASCO 2023. You were here to talk about, and you did talk about, cohort two for TALAPRO-2.
-
Jun 16, 2023 | 
urotoday.com | Karim Fizazi
In a discussion between Alicia Morgans and Karim Fizazi, they explore the quality of life outcomes from the VISION trial, published in Lancet Oncology. This Phase III trial examines the effects of Lutetium-PSMA-617 (also known as Pluvicto) on heavily pretreated metastatic castration-resistant prostate cancer patients. The study demonstrates a significant 38% reduction in the risk of death.
